Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk makes unsolicited offer for Metsera
05:57am, Thursday, 30'th Oct 2025
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera.
Novo Nordisk submits proposal to acquire Metsera, Inc.
05:49am, Thursday, 30'th Oct 2025
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports
05:47am, Thursday, 30'th Oct 2025
Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on
Pharmaceutical Stocks To Keep An Eye On – October 28th
02:09am, Thursday, 30'th Oct 2025
Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
06:20am, Wednesday, 29'th Oct 2025
Novo Nordisk is a major drugmaker offering treatments for diabetes and weight loss. Those are two conditions affecting millions of Americans.
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?
05:45am, Wednesday, 29'th Oct 2025
President Trump wants to cut the price of Ozempic to $150. While that could be an issue for Novo Nordisk, it should find a way to navigate ongoing price negotiations.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
06:46pm, Tuesday, 28'th Oct 2025
Novo Nordisk (NVO) closed at $52.05 in the latest trading session, marking a -1.59% move from the prior day.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:01am, Monday, 27'th Oct 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market
02:24pm, Friday, 24'th Oct 2025
Initiating coverage on Novo Nordisk (NVO) with a Strong Buy 70% below its all-time high. NVO's competitive pressures and US political pricing risks are mid-term noise. Global obesity and diabetes mark
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
12:41pm, Friday, 24'th Oct 2025
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
Novo Nordisk: The fog begins to lift
10:31am, Friday, 24'th Oct 2025
It has been a jittery few months for Novo Nordisk (NYSE:NVO) investors, but Berenberg thinks the worst of the uncertainty may be passing. The broker has reiterated its 'buy' rating and DKK 425 price t
Focus: Novo Nordisk's new chairman has 'carte blanche' after board clear-out
08:32am, Friday, 24'th Oct 2025
A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, rattling investors despite calls for stronger leadership at the drugmaker behin
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
10:56am, Thursday, 23'rd Oct 2025
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats
08:00am, Thursday, 23'rd Oct 2025
Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S.
Rep. Marjorie Taylor Greene Purchases Shares of Novo Nordisk A/S (NYSE:NVO)
02:10am, Thursday, 23'rd Oct 2025
Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S (NYSE: NVO). In a filing disclosed on October 20th, the Representative disclosed that they had bought betwe
